Primary AML cells were co-cultured with irradiated stromal cells and treated with DMSO as a control, 10 μM enzalutamide (n = 49; ELN 2022 risk: 9 favorable; 15 intermediate; 25 adverse) or 10 μM darolutamide (n = 65; ELN 2022 risk: 10 favorable; 18 intermediate; 37 adverse) alone, 200 μM cytarabine alone, and a combination of cytarabine with AR blockers in the presence of 10 nM DHT or 1 nM R1881. Here, AR is linked to acute myeloid leukemia.